The Importance of Lifestyle Integration It is vital to understand that GLP-1 medications should not be viewed as a standalone solution
Underlying health conditions, such as hypothyroidism or PCOS, may slow your progress and are worth discussing with a licensed healthcare provider
Building on these research findings, Eli Lilly developed a dual agonist targeting GLP-1R/GIPR, called tirzepatide, which was approved by the FDA in 2022 and showed promising therapeutic effects for T2D and obesity
Lowering calorie intake leads to slow and sustainable weight loss
Trial participation provides access to investigational treatments while contributing to the evidence base that ultimately benefits all Canadians
If you're taking a medication or following an eating protocol that puts you in a significant calorie deficit, its imperative to stay mindful of your nutrient intake